Mobile Trading

BIOCON LTD.

NSE : BIOCONBSE : 532523ISIN CODE : INE376G01013Industry : Pharmaceuticals & DrugsHouse : Private
BSE264.107.5 (+2.92 %)
PREV CLOSE ( ) 256.60
OPEN PRICE ( ) 257.55
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 1492284
TODAY'S LOW / HIGH ( )257.55 266.70
52 WK LOW / HIGH ( )199.3 307
BSE
1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Incorporation Year : 29-11 1978
Management Info
Kiran Mazumdar-Shaw - Chairman Siddharth Mittal - Managing Director
Registered Office

Address 20th Km,Hosur Road,Electronic City,
Bengaluru,
Karnataka-560100

Phone 080 2808 2808

Email corporate.communications@biocon.com

Website www.biocon.com

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, MCX
NEWS
28Mar Biocon gets approval from MHRA, UK for
Biocon has received approval from the Medicines and Healthcare Products..
28Mar Biocon shines on getting approval from
Biocon is currently trading at Rs. 260.55, up by 3.95 points or 1.54% fr..
28Mar Biocon informs about trading window cl
Pursuant to the provisions of SEBI (Prevention of Insider Trading) Regul..
23Mar Biocon informs about newspaper adverti
Further to its letter dated March 21, 2024 regarding intimation of Posta..
16Mar Biocon informs about loss of share cer
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclo..
Financials
in Millions
QTR Dec 23 ANNUAL 23
Net Profit24028484
Gross Profit 329 29712
Operating Profit 11982949
Net Sales 562819929
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group
Abbott India (BSE)
up  26946.00 (0.74%)
M.Cap ( in Cr)57258.37
Sanofi India (BSE)
up  8118.25 (2.06%)
M.Cap ( in Cr)18696.83
Dr. Reddy's Lab (BSE)
up  6155.15 (1.78%)
M.Cap ( in Cr)102679.14
Divi's Lab (BSE)
up  3436.75 (2.14%)
M.Cap ( in Cr)91234.91
Glaxosmithkline Phar (BSE)
up  1943.10 (3.26%)
M.Cap ( in Cr)32917.29
Shareholding Pattern
MUTUAL FUNDS/UTI 9.31%
PROMOTERS 60.64%
FI/BANKS/INSURANCE 5.12%
NON-INSTITUTION 18.3%
GOVERNMENT 0%
FII 0%
  • attention investors
  • kyc
  • ipo
  • ibt trading

Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020.

Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.

Pay 20% upfront margin of the transaction value to trade in cash market segment.

Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard.

Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month.
.......... Issued in the interest of Investors

INVESTOR CHARTER
© 2018 Ratnakar Securities Pvt. Ltd. All rights reserved.
Designed, Developed & Content Powered by  Accord Fintech Pvt. Ltd.
CLOSE X

Filing complaints on SCORES Easy & quick

  • > Register on SCORES portal (link:https://scores.gov.in)
  • > Mandatory details for filing complaints on SCORES
    • Name
    • PAN
    • Address
    • Mobile Number
    • E-mail ID
  • > Benefits:
    • Effective communication
    • Speedy redressal of the grievances
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.